We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Teradyne (TER) This Earnings Season?
Read MoreHide Full Article
Teradyne Inc. (TER - Free Report) is slated to report second-quarter 2020 results on Jul 21. In the last reported quarter, it delivered a positive earnings surprise of 16.3%.
The stock outperformed earnings estimates in all the trailing four quarters, with the average surprise being 11.03%.
Trend in Estimate Revision
For the second quarter, the Zacks Consensus Estimate for earnings has remained stable at $1.02 per share over the past 30 days. This indicates an increase of 54.6% from the year-ago reported figure.
The consensus mark for revenues is pegged at $749.4 million, implying an increase of 32.8% from the year-ago reported figure.
Let’s see how things have shaped up for this announcement.
Teradyne’s demand for test equipment in the second quarter is expected to have been low due to the COVID-19 pandemic.
Nevertheless, semiconductor Test revenues are likely to have got a boost in second-quarter 2020 owing to persistent growth in 5G infrastructure, strengthening of mobility, strong networking and growing memory test spending. The Zacks Consensus Estimate for Semiconductor Test revenues is currently pegged at $539 million, indicating a 11.4% year-over-year increase.
Markedly, the Industrial Automation business saw a decline in the last reported quarter. The trend is expected to have continued in the to-be-reported quarter as Europe and North American manufacturing remains impacted by coronavirus-led shutdowns.
The Zacks Consensus Estimate for Industrial Automation revenues is currently pegged at $55 million, suggesting a 8.3% year-over-year decline.
Increasing complexity of processors and technologies, popularity of its products, growing demand for millimeter wave test capabilities — both in Semi Test and at LitePoint — and continued design wins are expected to have driven Teradyne’s performance in the to-be-reported quarter.
However, weakness in a few end markets served by the company could have been a headwind during the quarter. Also, increasing headwinds due to the COVID-19 pandemic may impact the results for the quarter to be reported.
For the to-be-reported quarter, management expects total revenues in the range of $690-$800 million. Non-GAAP earnings per share from continuing operations are likely to be in the range of 86 cents to $1.16.
What Our Model Says
Our proven model does not conclusively predict an earnings beat for Teradyne this time around. The combination of a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here as you will see below.
Earnings ESP: The company has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Currently, Teradyne has a Zacks Rank #2.
Stocks to Consider
Here are a few stocks that you may want to consider, as our model shows that these have the right combination of elements to post a positive earnings surprise in the quarter to be reported.
NXP Semiconductors N.V. (NXPI - Free Report) has an Earnings ESP of +11.90% and holds a Zacks Rank of 2.
Expedia (EXPE - Free Report) has an Earnings ESP of +12.98% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
What's in Store for Teradyne (TER) This Earnings Season?
Teradyne Inc. (TER - Free Report) is slated to report second-quarter 2020 results on Jul 21. In the last reported quarter, it delivered a positive earnings surprise of 16.3%.
The stock outperformed earnings estimates in all the trailing four quarters, with the average surprise being 11.03%.
Trend in Estimate Revision
For the second quarter, the Zacks Consensus Estimate for earnings has remained stable at $1.02 per share over the past 30 days. This indicates an increase of 54.6% from the year-ago reported figure.
The consensus mark for revenues is pegged at $749.4 million, implying an increase of 32.8% from the year-ago reported figure.
Let’s see how things have shaped up for this announcement.
Teradyne, Inc. Price and EPS Surprise
Teradyne, Inc. price-eps-surprise | Teradyne, Inc. Quote
Factors to Note
Teradyne’s demand for test equipment in the second quarter is expected to have been low due to the COVID-19 pandemic.
Nevertheless, semiconductor Test revenues are likely to have got a boost in second-quarter 2020 owing to persistent growth in 5G infrastructure, strengthening of mobility, strong networking and growing memory test spending. The Zacks Consensus Estimate for Semiconductor Test revenues is currently pegged at $539 million, indicating a 11.4% year-over-year increase.
Markedly, the Industrial Automation business saw a decline in the last reported quarter. The trend is expected to have continued in the to-be-reported quarter as Europe and North American manufacturing remains impacted by coronavirus-led shutdowns.
The Zacks Consensus Estimate for Industrial Automation revenues is currently pegged at $55 million, suggesting a 8.3% year-over-year decline.
Increasing complexity of processors and technologies, popularity of its products, growing demand for millimeter wave test capabilities — both in Semi Test and at LitePoint — and continued design wins are expected to have driven Teradyne’s performance in the to-be-reported quarter.
However, weakness in a few end markets served by the company could have been a headwind during the quarter. Also, increasing headwinds due to the COVID-19 pandemic may impact the results for the quarter to be reported.
For the to-be-reported quarter, management expects total revenues in the range of $690-$800 million. Non-GAAP earnings per share from continuing operations are likely to be in the range of 86 cents to $1.16.
What Our Model Says
Our proven model does not conclusively predict an earnings beat for Teradyne this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here as you will see below.
Earnings ESP: The company has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Currently, Teradyne has a Zacks Rank #2.
Stocks to Consider
Here are a few stocks that you may want to consider, as our model shows that these have the right combination of elements to post a positive earnings surprise in the quarter to be reported.
NXP Semiconductors N.V. (NXPI - Free Report) has an Earnings ESP of +11.90% and holds a Zacks Rank of 2.
Netflix, Inc. (NFLX - Free Report) has an Earnings ESP of +2.27% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Expedia (EXPE - Free Report) has an Earnings ESP of +12.98% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>